Reprint
Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases
Edited by
May 2023
190 pages
- ISBN978-3-0365-7739-5 (Hardback)
- ISBN978-3-0365-7738-8 (PDF)
This book is a reprint of the Special Issue Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases that was published in
Biology & Life Sciences
Medicine & Pharmacology
Summary
The Special Issue of Biomedicines, entitled “Advances in Pathogenesis and Therapeutics of Hepatobiliary Diseases,” presents cutting-edge research findings, innovations, and insights into a wide range of topics related to the hepatobiliary system, such as the molecular mechanisms underlying disease pathogenesis, diagnostic advancements, novel therapeutic approaches, and prevention strategies. The Special Issue comprises seven original articles and four review articles regarding NAFLD, primary biliary cholangitis (PBC), hepatitis B and C, and hepatocellular carcinoma (HCC).
Format
- Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
PBC; autoantibodies; glycoprotein gp210; nucleoporin p62; KLHL12 peptide; hepatitis B virus; hepatitis B X open reading frame; HBX 3′ end region; insertions; deletions; quasispecies; next-generation sequencing; cholestatic diseases; gene therapy; AAV; PFIC; RUNX1; NAFLD; NASH; metabolism; systems biology; PBC; ursodeoxycholic acid (UDCA); obeticholic acid (OCA); fibrates; FXR agonists; PPAR agonists; budesonide; transarterial chemoembolization; radiofrequency ablation; hepatocellular carcinoma; type 2 diabetes mellitus; non-alcoholic fatty liver disease; transient hepatic elastography; hepatic steatosis; liver fibrosis; primary biliary cholangitis; obeticholic acid; ursodeoxycholic acid; farnesoid X receptor; HCV; DAA; mitochondria; genotoxicity; side effect; chronic hepatitis B; nucleos(t)ide analogs; miR-125b; hepatitis B virus; biomarker; fibrosis score; fatty liver; cirrhosis; females; gender; liver; n/a